Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Douglas Sites, Kristopher Wood

Premium

Douglas Sites has joined Rosetta Genomics as its executive vice president of sales and marketing, a newly created position. Before Rosetta, Sites was vice president of sales and marketing at Asuragen. Prior to that, he served as director of sales for hematology and oncology at Plus Diagnostics.


Nanosphere has appointed private equity investor Kristopher Wood to its board of directors.

Wood is the sole member of Highline Partners, a consultancy through which he serves as chief investment officer at Lurie Holdings, and special advisor on strategic matters to New Page Corporation.

Before forming Highline, Wood was head of strategy and corporate development at WorldColor Press, as well as an associate at the private equity firm MidOcean Partners. He also was chief acquisitions officer for Glenayre, and managing director for mergers and acquisitions and venture capital at Vertis Holdings.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.